Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts

Leukemia

Volumn 17, Issue 2, 2003, Pages 319-322

  Ribrag, V ^a   Suzan, F ^a   Ravoet, C ^f   Feremans, W ^g   Guerci, A ^d   Dreyfus, F ^c   Damaj, G ^b   Vantelon, J M ^a   Bourhis, J H ^a   Fenaux, P ^e  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c Hôpital Cochin ^*  (France)

^d UNIVERSITY HOSPITAL OF NANCY   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f Hospital de Jolimont   (Belgium)

^g NONE

Author keywords

Chemotherapy; Irinotecan; Myelodysplastic syndromes

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTHRACYCLINE DERIVATIVE; CYTARABINE; DNA TOPOISOMERASE INHIBITOR; IRINOTECAN; LOPERAMIDE; MELPHALAN; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLAST CELL; BLOOD TOXICITY; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DIARRHEA; DRUG DOSE REGIMEN; FEMALE; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; MALE; MYCOSIS; MYELODYSPLASTIC SYNDROME; OUTPATIENT CARE; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REFRACTORY ANEMIA; TUMOR LYSIS SYNDROME;

EID: 0037330985     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402726     Document Type: Article

References (25)

1. Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1985; 59: 425-433.
2. Oscier DG. Myelodysplastic syndromes. Clin Haematol 1987; 1: 389-426.
3. Fenaux P. Myelodysplastic syndromes. Hematol Cell Ther 1996; 38: 363-380.
4. Sutton L, Chastang C, Ribaud P, Jouet JP, Kuentz M, Attal M, Rieffers J, Tigaud JM, Rio B, Dauriac C, Legros F, Dreyfus F, Lioure B, Troussard X, Milpied M, Witz F, Oriol P, Cahn JY, Michallet M, Gluckman E, Ifrah N, Pico JL, Vilmer E, Leblond V. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long term study of 71 patients. Société Française de Greffe de Moelle. Blood 1996, 88: 358-365.
5. Anderson JE, Appelbaum FR, Fisher LD, Schoch G, Shulman H, Anasetti C, Besinger WI, Bryant E, Buckner CD, Doney K, Martin PJ, Sander JE, Sullivan KM, Thomas ED, Witherspoon RP, Hansen JA, Storb R. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 1993; 82: 677-681.
6. De Witte T, Suciu S, Verhoef G, Labar B, Archimbaud E, Aul C, Selleslag D, Ferrant A, Wijermans P, Mandelli F, Amadori S, Jehn U, Muus P, Boogaerts M, Zittoun R, Gratwohl A, Zwierzina H, Hagemeijer A, Willemze R. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes or acute myeloid leukemia following MDS. Blood 2001; 98: 2326-23331.
7. Wattel E, De Botton S, Lao JL, Pruedhomme C, Lepelley P, Bauters F, Fenaux P. Long-term follow-up of de novo myelodysplatic syndromes treated with intensive chemotherapy: incidence of long-term survivors and outcome of partial responders. Br J Haematol 1997; 98: 983-991.
8. Cheson BD, Simon R. Low-dose ara-C in acute non-lymphocytic leukemia and myelodysplastic syndrome: a review of 20 years' experience. Semin Oncol 1987; 14: 126-133.
9. Miller KB, Kyungmann K, Morison FS, Winter JN, Bennet JM, Neiman RS, Head DR, Gassileth PA, O'connell MJ. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase III intergroup study. Ann Hematol 1992; 65: 162-168.
10. Denzlinger C, Bowen D, Benz D, Gelly K, Burgger W, Kanz L. Low-dose melphalan induces favorable responses in elderly patients with high-risk myelodysplastic syndromes or secondary acute myeloid leukemia. Br J Haematol 2000; 108: 93-95.
11. Wijermans P, Lobbert M, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A. Low-dose 5-Aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000; 18: 956-962.
12. Andreeff M, Stone R, Michaeli J, Young CW, Tong WP, Sogoloff H, Ervin T, Kufe D, Rifkind RA, Mark PA. Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. Blood 1992; 80: 2604-2609.
13. Beran M, Kantarjian H. Topotecan in the treatment of hematologic malignancies. Semin Hematol 1998; 35: 26-31.
14. Bearn M, Estey E, O'Brien S, Cortes J, Koller CA, Giles FJ, Kornblau S, Andreef M, Vey N, Pierce SR, Hayes K, Chaun Wong G, Keating M, Kantarjian H. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol 1999; 17: 2819-2830.
15. Cheson BD, Bennet JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, Lövenberg B, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Gore S, Greenberg PL. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671-3674.
16. Abigerges D, Armand JP, Chabot GG, Da Costa L, Fadel E, Cote C, Hérait P, Gandia D. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 1994; 86: 446-449.
17. Greenberg P, Cox C, Le Beau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennet JM. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
18. Arbuck SG, Takimoto CH. An overview of topoisomerase I targeting agents. Semin Hematol 1998; 35: 3-12.
19. Pommier Y. DNA topoisomerase I and II in cancer chemotherapy: update and perspective. Cancer Chemother Pharmacol 1993; 32: 103-108.
20. Ohno R, Okada K, Masaoka T, Kuramato A, Arima T, Yoshida Y, Ariyoshi H, Ichimaru M, Sakai Y, Oguro M, Ito Y, Morishima Y, Yokomaku S, Ota K. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 1990; 8: 1907-1912.
21. Niitsu N, Iijima K, Chizuka A. Combination therapy with irinotecan (CPT-11), mitoxantrone, and dexamethasone in relapsed or refractory non-Hodgkin's lymphoma: a pilot study. Ann Hematol 2001; 80: 411-416.
22. Saotome T, Takagi T, Sakai C, Kumagai K, Tamaru J. Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin's lymphoma. Ann Oncol 2000; 11: 115-116.
23. Tsuda H, Takatsuki K, Ohno R, Masaoka T, Okada K, Shirakawa S, Ohashi Y, Ota K. Treatment of adult T-cell leukemia-lymphoma with irinotecan hydrochloride (CPT-11). Br J Cancer 1994; 70: 771-774.
24. Rothenberg ML, Kuhn JG, Burris HA 3rd, Nelson J, Eckardt JR, Tristan-Morales M, Hilsenbeck SG, Weiss GR, Smith LS, Rodriguez GI. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 1993; 11: 2194-21204.
25. Abigerges D, Chabot GG, Armand JP, Hérait P, Gouyette A, Gandia D. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995; 13: 210-221.